Primary Prevention of Osteoporosis in Postmenopausal Women

Introduction to Osteoporosis Prevention

The American College of Physicians recommends initiating oral bisphosphonates combined with calcium and vitamin D for postmenopausal women at high risk of fracture, as this represents the most effective primary prevention strategy with proven reduction in vertebral, nonvertebral, and hip fractures 1, 2

The National Osteoporosis Foundation suggests screening all women aged 65 years and older with DXA scanning of the spine and hip to identify those requiring pharmacologic intervention 3, 4
For postmenopausal women under age 65 with risk factors, perform DXA screening earlier 3, 4
A T-score ≤ -2.5 on DXA confirms osteoporosis diagnosis and warrants immediate pharmacologic treatment 1, 5

The American College of Physicians recommends oral bisphosphonates as the preferred initial therapy based on superior safety profile, extensive clinical experience, proven fracture reduction, and low cost compared to all alternatives 1, 2
Alendronate 70 mg once weekly is a preferred generic formulation 6, 2
Risedronate 35 mg once weekly or 150 mg monthly is an alternative option 6, 2
Zoledronic acid 5 mg IV annually is an option for patients unable to tolerate oral formulations 2, 5

Bisphosphonates reduce vertebral fractures by 47-56% over 3 years 1, 2
Bisphosphonates reduce hip fractures by 50% in high-risk patients 2
Bisphosphonates reduce nonvertebral fractures with relative risk 0.83 3, 4
No difference in serious adverse events compared to placebo in randomized trials 2

All postmenopausal women receiving osteoporosis treatment must take calcium 1,200 mg daily and vitamin D 800 IU daily, as pharmacologic therapy is significantly less effective without adequate supplementation 6, 2, 5
Calcium and vitamin D alone are insufficient for fracture prevention in those with established osteoporosis 7, 1

Implement weight-bearing exercise, smoking cessation, alcohol limitation, and fall prevention strategies as these reduce fracture risk independent of pharmacologic therapy 7, 2

For patients with contraindications to or intolerance of bisphosphonates, use denosumab 60 mg subcutaneously every 6 months as second-line therapy 1, 5
Denosumab reduces vertebral, nonvertebral, and hip fractures in postmenopausal women 1
Never discontinue denosumab abruptly, as this causes rebound bone loss and multiple vertebral fractures 5

For postmenopausal women at very high risk, consider anabolic agents as initial therapy, followed by mandatory transition to bisphosphonate 1, 6

Treat initially for 5 years with bisphosphonates, then reassess fracture risk to determine if continuation is warranted 2, 5
Do not monitor bone density during the initial 5-year treatment period, as this provides no clinical benefit 2, 5

Educate patients on proper bisphosphonate administration, expected duration of therapy, importance of adherence, and necessity of calcium/vitamin D supplementation 6, 2
Emphasize that osteoporosis is asymptomatic until fracture occurs, making adherence critical 6

Never use calcium and vitamin D alone as primary prevention in patients with established osteoporosis (T-score ≤ -2.5) 7, 1
Never prescribe expensive brand-name medications when generic bisphosphonates are equally effective 2
Never discontinue denosumab without transitioning to bisphosphonate 5